That solid Type 1 mandible that feels so secure? It’s healing ten times slower than you think. But there’s a way around it — and it’s the opposite of what most courses teach.

The Reassuring Lie of Dense Bone

Dense bone feels reassuring.

That solid Type 1 mandible provides excellent primary stability. You engage cortex confidently. The implant feels secure. Placement feels successful.

But here’s what nobody tells you: biological integration follows different rules than mechanical grip.

The scientific literature reveals a paradox that most implant courses gloss over — and I mean completely gloss over. The densest bone types heal the slowest. Not marginally slower. Dramatically slower.

Understanding why this happens — and what you can actually do about it — separates clinicians who follow protocols from those who understand biology.

Let me show you what’s actually happening in that dense mandible.

Why Cortical Bone Starves: The Haversian Problem

Before we talk about rates, you need to understand the anatomy.

Cortical bone has one fundamental limitation: its blood supply is restricted to Haversian and Volkmann canals. These are tiny channels running through an otherwise dense, mineralised matrix. That’s it. There is no open marrow space, no spongy trabecular network with large vascular sinusoids. Every red blood cell reaching the osteocytes inside cortical bone must travel through these microscopic tunnels.

Trabecular bone is the opposite. It’s an open lattice of bony trabeculae surrounded by marrow, rich with blood vessels, stem cells, and the full cellular machinery of regeneration. When you create an osteotomy in trabecular bone, you open directly into this vascular network. Blood floods the site.

When you drill into dense cortical bone, you’re cutting through a structure where the nearest blood vessel may be hundreds of micrometres away, locked inside a Haversian system.

This anatomical reality drives the numbers that Albrektsson (1980) and Rhinelander (1974) documented:

That is a tenfold differential. And it’s not because cortical bone is biologically reluctant to heal. It’s because the vascular infrastructure simply isn’t there to support rapid revascularisation.

When you place an implant in Type 1 bone, the bone immediately surrounding the implant surface must revascularise to support the healing process. At 0.05mm daily, this revascularisation crawls — potentially leaving the peri-implant bone in a hypoxic state for extended periods.

And hypoxia in bone is not benign.

The Hypoxia-Inflammation Cascade

Here’s the biological sequence that unfolds in dense cortical bone:

Stage 1: Cortical bone surrounds the implant — Haversian and Volkmann canals are the sole vascular channels

Stage 2: Slow angiogenesis (0.05mm/day) means delayed revascularisation of the peri-implant zone

Stage 3: Hypoxia persists at the implant interface

Stage 4: Hypoxia generates oxidative stress

Stage 5: Oxidative stress maintains M1 macrophage persistence

Stage 6: The M1-dominant environment favours inflammation over regeneration

This is the cascade most clinicians never learned. You placed the implant perfectly. You achieved excellent primary stability. But the biology is working against you because the vascular architecture of cortical bone cannot deliver blood fast enough to support the healing your implant needs.

The consequence? Delayed osseointegration, variable integration quality, or in severe cases, compromised outcomes that simply would not occur in more vascularised bone.

Same surgeon. Same technique. Different biology.

Now Add Compression — And You Make It Worse

Here’s where standard practice compounds the problem.

The default approach for most implant systems — and most training courses — is to undersize the osteotomy. The logic seems sound: tighter fit means higher insertion torque means better primary stability.

But think about what you’re actually doing in Type 1 bone. You’re compressing an already poorly vascularised structure. The Haversian and Volkmann canals that represent the sole blood supply to cortical bone? You’re crushing them.

Undersized drilling in dense bone creates compressive forces along the entire bone-implant interface. This compression generates microcracks, damages osteocytes, and — critically — occludes the already sparse vascular channels. The bone around your implant doesn’t just heal slowly because it’s cortical. It heals slowly because you’ve destroyed what little blood supply it had.

The clinical signature is well documented: ISQ values drop through weeks 2-4 as compressed bone undergoes necrosis and resorption before new bone can form. This is the classic “stability dip” — and in Type 1 bone, it’s deeper and longer than anywhere else.

You achieved high insertion torque. But you paid for it with biology.

The Intelligent Alternative: Oversized Osteotomy Preparation

What if, instead of compressing cortical bone, you deliberately created space?

This is the principle behind oversized drilling — and in 2021, Seleem, Tawfik, and El-Nahass published the first randomised controlled trial specifically investigating this approach in vivo.

Their trial placed 20 implants in the posterior maxilla, randomised into two groups: manufacturer-recommended osteotomy preparation versus oversized drilling (final drill 0.2mm wider than the implant diameter, inserted to half the implant length). The oversized group achieved primary stability through apical engagement only — the coronal 3-5mm of the implant sat within a slightly wider osteotomy.

An important caveat: this trial was conducted in the posterior maxilla, where bone is predominantly trabecular. Even in this more forgiving environment, the benefits of eliminating compression were clear. The biological rationale transfers directly to cortical bone — and is arguably more important there, where the vascular architecture is genuinely sparse and every Haversian canal matters.

The results were striking.

Stability: The manufacturer-recommended group showed the classic stability dip — ISQ values dropped from 70.3 at baseline to 53.6 at week 4 before recovering. The oversized group showed no dip at all. ISQ values climbed steadily from 52.4 at baseline to 77.6 at week 12. By week 2, the oversized group had already overtaken the control group — and never looked back.

Crestal bone: At 6 months, the oversized group showed significantly less crestal bone loss (0.91mm versus 1.3mm in the control group, P = .00).

Pain: 100% of the oversized group reported zero pain from day 0. In the control group, over 85% reported pain scores of 2-3 during the first four days.

Survival: Both groups achieved 100% survival at 6 months.

Why This Works: Blood Clot, Not Bone Compression

The biological rationale is elegant and it connects directly to the Haversian problem.

When you oversize the coronal portion of the osteotomy, you completely eliminate compressive forces at the crestal bone. Instead of crushing Haversian canals shut, you create a controlled gap between the implant surface and the osteotomy wall.

What fills that gap? A blood clot. Forming in direct apposition to the implant surface.

This is fundamentally different from the undersized scenario. Instead of necrotic compressed bone requiring resorption before new bone can form, you have a fibrin scaffold populated with platelets, growth factors, and mesenchymal stem cells — the complete biological toolkit for intramembranous bone formation.

The implant still achieves primary stability. It’s just coming from apical engagement (1-2mm into denser bone or bicortical purchase) rather than circumferential compression. The coronal biology is liberated to heal through direct bone apposition rather than remodelling through a necrosis-resorption-formation sequence.

This is why the Seleem data shows no stability dip. There is no compressed bone to resorb. Secondary stability begins building from day one.

Two Strategies for Dense Bone

Understanding this biology gives you two intelligent approaches to Type 1 bone:

Strategy 1: Overpreparation with Apical Engagement

Prepare the osteotomy to full diameter (or slightly oversized) through the cortical bone, with the implant achieving primary stability from apical engagement only. The coronal 3-5mm sits within a wider preparation, allowing blood clot formation against the implant surface. This is the Seleem protocol.

Best for: Single-stage placement where you want to eliminate the stability dip and accelerate secondary stability.

Strategy 2: Overpreparation with Delayed Placement

Prepare the osteotomy, place platelet-rich autogenous blood clots, and allow the site to heal. Then place the implant at a later date, targeting the point in the healing cascade where mineralisation and vascularity are beautifully balanced — you’re placing into regenerated, well-vascularised bone rather than the original dense cortex.

Best for: SPSIs (sintered porous-surfaced implants) or situations where you want to convert a hostile Type 1 environment into a biologically favourable one before placement.

Both strategies share the same principle: stop fighting the biology of cortical bone and start working with it.

The Misch-Lekholm Classification — Through an Angiogenesis Lens

You know the bone classification system. But understanding these bone types through vascular biology reveals clinical implications most courses never mention.

Type 1: Dense Cortical

Vascular architecture: Haversian and Volkmann canals only. Angiogenesis 0.05mm/day.

What this actually means: This is the bone type that feels the most secure during placement but requires the most intelligent protocol modification. Full osteotomy preparation (no undersizing). Consider overpreparation at the crest. Copious irrigation is essential — you’re generating heat in dense bone with poor blood supply, and thermal damage is cumulative. Extended healing timelines are not optional. SPSIs are contraindicated unless using the delayed placement strategy above.

Type 2: Thick Cortical with Coarse Trabecular Core

This is the clinical ideal — cortical stability from the shell with trabecular blood supply from the core. Standard protocols work as advertised. The trabecular component provides the vascular highway that Type 1 lacks.

Type 3: Thin Cortical with Fine Trabecular

Angiogenesis profile: moderate to rapid. The vascularity is working in your favour. Consider undersizing the osteotomy for stability — here, unlike Type 1, the surrounding bone can tolerate mild compression because the open trabecular network maintains blood flow around the compressed zone.

Type 4: Fine Trabecular, Minimal Cortical

Angiogenesis 0.5mm/day. Excellent revascularisation. Undersizing and condensation protocols needed for primary stability, but once you achieve stability, healing biology is on your side. SPSIs are ideal here — the rapid angiogenesis supports 3D bone ingrowth into the porous surface beautifully.

The irony: the bone type that feels least secure during placement often has the best healing biology. The bone type that feels most secure often has the worst.

The Khoury Technique: The Same Biology at Work

Khoury’s split bone block technique demonstrates these angiogenesis principles in clinical practice. It is a beautiful example of understanding biology rather than just following technique.

Traditional Block Grafting: Solid corticocancellous blocks placed against the recipient site. Blood vessels must penetrate through that cortical shell. At 0.05mm per day through Haversian canals. You’re waiting 6-8 months.

Khoury’s Modification: Blocks thicker than 3mm are split into a thin cortical shell with particulate cancellous on the intaglio surface. Blood vessels now penetrate through the particulate portion at 0.5mm per day. Ten times faster.

The clinical outcome: 4-month healing where conventional blocks require 6-8 months. Same graft volume, same mechanical containment, but revascularisation follows the biology rather than fighting it.

This is the same principle as oversized drilling. In both cases, you’re creating conditions where blood — not compressed bone — is in contact with the surface that needs to integrate.

Sintered Porous-Surfaced Implants: A Special Case

SPSIs achieve fixation through osseoconsolidation — 3D bone ingrowth into a porous titanium surface (35-40% porosity). For bone to grow into the porous structure, blood vessels must penetrate those pores first. No blood supply, no bone ingrowth.

In Type 1 bone, the 0.05mm/day angiogenesis rate through Haversian canals makes this process prohibitively slow. This is a biological contraindication, not merely a suggestion.

The workaround — and it’s an elegant one — is the delayed placement strategy: create the osteotomy, place platelet-rich blood clots, let the site heal, and return when the cortical bone has been replaced by well-vascularised regenerate. Now you’re placing your SPSI into biology that can support osseoconsolidation.

Conversely, SPSIs in Type 4 bone are ideal. The rapid angiogenesis supports 3D bone ingrowth beautifully. The porous structure that’s a liability in dense bone becomes an advantage in vascular bone.

Same implant. Different bone type. Completely different biological outcome.

The Question You Need to Answer

The angiogenesis paradox teaches a fundamental lesson: mechanical stability and biological integration follow different rules.

Dense bone provides excellent grip. But excellent grip through compression may actively compromise healing by destroying the sparse vascular channels that cortical bone depends on.

Oversized drilling is not counterintuitive once you understand the biology. It’s the logical response to the vascular anatomy of cortical bone. You trade compressive primary stability for a blood clot scaffold — and the evidence suggests you get faster secondary stability, less crestal bone loss, and less patient morbidity in return.

So here’s the question: do you assess bone type and modify your osteotomy protocol accordingly?

Not just “Type 1 versus Type 4” as a classification exercise, but as a vascular reality that changes your drilling diameter, your approach to crestal preparation, your healing timeline, and your implant selection?

Because the biology says you should.

At the Academy of Implant Excellence, we teach the biology behind the protocols. Understanding why cortical bone heals differently — down to the Haversian canal level — is one example of the depth that changes practice. Not because it’s complicated, but because most courses teach bone classification as a chart to memorise rather than a biological reality that fundamentally alters clinical decisions.

And once you understand that the vascular architecture of bone dictates healing, not the insertion torque, you can’t go back to treating all bone types the same.

Ready to Understand the Biology Behind the Protocols?

The Academy of Implant Excellence teaches system-agnostic, biology-first implant training. From single implants to full-arch mastery. 80+ hours of depth that covers the invisible 10% where complications happen.

Because protocols work until they don’t.

[Explore Academy Training –>]

References

Albrektsson T. The healing of autologous bone grafts after varying degrees of surgical trauma. J Bone Joint Surg Br. 1980;62-B(3):403-410.

Rhinelander FW. Tibial blood supply in relation to fracture healing. Clin Orthop Relat Res. 1974;(105):34-81.

Seleem A, Tawfik OK, El-Nahass H. Evaluation of oversized drilling on implant survival and stability versus traditional drilling technique: a randomized clinical trial. Int J Oral Maxillofac Implants. 2021;36:771-778.

Khoury F et al. Autogenous Bone Harvesting and Grafting. Quintessence, 2022.

Deporter D, Ketabi M (eds). Short and Ultra-Short Implants. Quintessence, 2018.

Gruber R. Bone Biology and Grafting. In: Khoury F et al. Autogenous Bone Harvesting and Grafting. Quintessence, 2022.

Marin C, Granato R, Suzuki M, et al. Histomorphologic and histomorphometric evaluation of various endosseous implant healing chamber configurations at early implantation times: a study in dogs. Clin Oral Implants Res. 2010;21:577-583.

Berglundh T, Abrahamsson I, Lang NP. De novo alveolar bone formation adjacent to endosseous implants. Clin Oral Implants Res. 2003;14:251-262.

The rules haven’t been abandoned. They’ve been refined.

What You Were Taught

The teaching was straightforward, and it made sense at the time.

Infected sites require healing before implant placement. Compromised sockets need staged approaches. Molars are too challenging for immediate implants.

These principles protected patients during an era when immediate placement protocols were still developing. Conservative approaches minimised risk when outcomes were uncertain.

But here’s what’s changed: the evidence base has matured significantly.

What was once contraindicated may now be indicated—with appropriate case selection and technique modification.

This isn’t about being aggressive. It’s about understanding that “contraindicated” and “indicated” aren’t fixed categories. They’re decision gates based on specific anatomical and pathological criteria.

Let me show you when the contraindications no longer apply.

Scenario 1: The Infected Site

The old rule: infection = delay placement.

The refined rule: it depends on the type of infection.

Acute Infection (True Contraindication)

What you see:

Management: Extraction, thorough debridement, antibiotics, delayed placement.

This hasn’t changed. Active suppuration means you cannot achieve the sterile field needed for osseointegration. Don’t try. Wait.

Chronic Infection (Proceed with Modification)

What you see:

Management: Immediate placement with thorough debridement protocol.

This is the refinement. Chronic periapical pathology without active infection can be managed at the time of extraction. The key is complete removal of the granulation tissue and inflammatory debris.

Decision Gate:

Chronic infection (contained, no suppuration) = Proceed with thorough debridement

Acute infection (active suppuration) = Delay placement

The distinction is clinical and visual. If you can establish a clean, dry, sterile field after debridement, you can proceed. If you’re still seeing purulent discharge, you wait.

Scenario 2: The Compromised Buccal Plate

The old rule: thin or dehisced buccal plate = stage the treatment.

The refined rule: it depends on the severity of compromise.

Class I: Intact, Thick Buccal Plate (>1mm)

Treatment approach: Standard immediate implant protocol. No modifications needed.

This is the ideal scenario. Proceed with confidence.

Class II: Thin Buccal Plate (<1mm) or Dehiscence

Treatment approach: Vestibular Socket Therapy indicated.

What this means:

This is the key clinical insight: Class II sockets can be managed with regenerative protocols at the time of immediate placement. You don’t need to stage it. You need to augment it.

Class III: Absent or Severely Compromised Buccal Plate

Treatment approach: Staged approach or extensive augmentation required.

Why the distinction: The biological capacity for simultaneous regeneration has limits. Class III defects exceed those limits. Stage it.

Decision Gate:

Class I (>1mm thick) = Standard immediate placement

Class II (thin or small dehiscence) = Immediate placement + regenerative management

Class III (absent or severe compromise) = Stage the treatment

The classification gives you objective criteria. Measure the buccal plate. The measurement determines the protocol.

Scenario 3: The Molar Extraction Socket

The old rule: molars are too complex for immediate implants.

The refined rule: it depends on the interseptal ridge (IRS) anatomy.

The Smith-Tarnow IRS Classification:

This classification is based on whether the inter-radicular septum can provide primary stability.

Type A: IRS Contains Entire Osteotomy

Type B: IRS Smaller Than Osteotomy

Type C: Minimal or Absent IRS

Each type has appropriate protocols rather than blanket contraindication. The key is assessing the IRS height and width pre-operatively.

Ultra-Wide Molar Implants (The Game Changer)

Implants designed specifically for molar extraction sockets (8-9mm diameter) achieve 97.9% success rates when protocols are followed.

That’s not a typo. 97.9%.

But “when protocols are followed” is doing a lot of work in that sentence. Here are the critical requirements:

Non-negotiable rules:

If you violate the buccal contact rule, you compromise the thin buccal plate and invite resorption. The 2mm gap is not a guideline—it’s a requirement.

Decision Gate:

Favourable IRS anatomy (Type A or B) = Proceed with molar immediate placement protocol

Inadequate IRS (Type C) or inability to achieve stability = Modify approach or stage

The decision is anatomical, not philosophical.

The Stability Threshold Framework

Across all immediate placement scenarios, one variable overrides everything else: primary stability.

No stability = no osseointegration.

Here’s the framework:

Insertion Torque ≥35 Ncm:

Insertion Torque 25-35 Ncm:

Insertion Torque <15 Ncm:

The clinical decision: 35 Ncm or submerge.

If you’re hovering at 20-25 Ncm and trying to convince yourself it’s “probably fine,” it’s not. Submerge it. Stability is non-negotiable.

The Refined Rules

Contemporary evidence supports immediate placement in scenarios that traditional teaching called contraindicated.

But this isn’t about ignoring contraindications. It’s about precise case selection.

Chronic infection with thorough debridement: Proceed

Acute infection with suppuration: Wait

Class II socket with regenerative management: Proceed

Class III socket with severe buccal compromise: Stage

Molar with favourable IRS anatomy and protocol compliance: Proceed

Molar with inadequate stability or unfavourable anatomy: Modify or stage

The rules haven’t been abandoned. They’ve been refined from blanket prohibitions to specific anatomical and pathological criteria.

Do you assess these decision gates before immediate placement, or are you still following 2010 contraindications?

Because the evidence suggests you should be making decisions based on anatomy, not outdated blanket rules.

At the Academy, we teach the biology behind the protocols. Understanding when contraindications become indications with appropriate modification is one example of how evidence-based practice evolves. Not because the old rules were wrong, but because refined understanding allows us to expand indications safely.

And once you understand the specific criteria that determine success (IRS anatomy, infection type, buccal plate thickness, stability thresholds), you can’t go back to blanket contraindications.

Ready to Understand the Biology Behind the Protocols?

The Academy of Implant Excellence teaches system-agnostic, biology-first implant training. From single implants to full-arch mastery. 80+ hours of depth that covers the invisible 10% where complications happen.

Because protocols work until they don’t.

Explore Academy Training →

You’re choosing grafts by brand name. You should be choosing by biological programme.

The Promise Every Graft Makes

Every bone graft material makes the same promise: fill the defect, support healing, enable implant placement.

But not all grafts keep that promise the same way.

Some maintain volume by persisting as a permanent scaffold — the particles are still there years later, embedded in fibrous tissue. Others maintain volume temporarily while being completely transformed into living bone that remodels and integrates like native tissue.

The difference? It’s not the brand name. It’s not the marketing. It’s not even the species.

It’s whether the processing preserved the biological conditions that allow osteoclasts to do their job — attach, resorb, and replace graft with living bone.

There are two distinct mechanisms that enable this. And one processing approach that prevents it entirely.

Understanding this framework changes how you select materials. And once you understand it, you can’t go back to choosing grafts based on what the rep recommends.

The Two Pathways to Biological Turnover

For a graft material to be replaced by living bone, osteoclasts must be able to attach to it, resorb it, and initiate coupled remodelling — the same process that maintains your skeleton throughout life. There are two ways processing can preserve this capacity.

Pathway 1: Collagen-Mediated Turnover

Processing: Low temperature, below 130 degrees C, with collagen matrix preserved.

How it works: The preserved collagen contains RGD (arginine-glycine-aspartic acid) sequences — the molecular addresses that cells recognise as “this is bone matrix.” When macrophages encounter these sequences, integrin receptor binding occurs, triggering a signalling cascade that favours M2 polarisation. M2 macrophages drive regeneration rather than inflammation. Osteoclasts can attach to the collagen, resorb the material, and replace it with new bone through coupled remodelling.

The biological cascade:

RGD sequences intact –> integrin receptor binding –> M2 macrophage polarisation –> osteoclast attachment –> coupled remodelling –> vital bone replacement

What you get: A material that participates in biology. The graft doesn’t just sit there — it is actively recognised, resorbed, and replaced. Over 12-24 months, the graft particles disappear and living bone takes their place.

Examples: Dual-phase collagenated porcine xenografts (GTO, MP3) where the collagen matrix is deliberately preserved through low-temperature processing.

Pathway 2: Porosity-Mediated Turnover

Processing: Low temperature (130 degrees C), with all organic content removed — but native bone architecture preserved.

How it works: This is where it gets interesting, and where most courses get it wrong. Some materials remove all collagen and organic content — technically making them “deproteinised” — but because the processing temperature is low enough to avoid sintering, the native crystal structure, interconnected pore network, and surface characteristics of the original bone are preserved.

The key metric is porosity. When total porosity exceeds 75% with preserved macro-, micro-, and nanopore interconnectivity, the material provides a three-dimensional highway for fluid uptake, cell migration, and vascular invasion. The low crystallinity (because the hydroxyapatite was never sintered at extreme temperatures) means osteoclasts can engage and resorb the mineral. The interconnected pore system ensures blood reaches every part of the scaffold.

The biological cascade:

Native pore architecture preserved –> high porosity (greater than 75%) + interconnectivity –> rapid fluid uptake and cell migration –> low crystallinity enables osteoclastic resorption –> coupled remodelling –> vital bone replacement

What you get: A material that achieves the same endpoint as collagen-mediated turnover — active resorption and replacement by living bone — through a completely different mechanism. Instead of molecular recognition via RGD sequences, the turnover is driven by architectural fidelity. The material resorbs because its physical structure invites osteoclastic engagement, not because collagen tells cells what to do.

The evidence: Physicochemical characterisation shows porosity of 78.4% with a specific surface area of 69.9 m2/g — dramatically higher than high-temperature sintered bovine materials (62% porosity, 0.5 m2/g). In sinus augmentation, residual graft particles measured only 11.9% at 6 months and dropped to 6.1% by 12 months, while new bone formation rose from 18.9% to 40.2% over the same period. Histology confirms TRAP-positive multinucleated giant cells actively degrading the material. In head-to-head RCTs against sintered bovine xenograft, the porcine material showed comparable new bone formation but with smaller residual particles at the same timepoint — confirming faster turnover.

Examples: Deproteinised porcine bone mineral processed at low temperature with preserved native architecture (THE Graft, Purgo Biologics).

The Third Category: Structural Persistence

High-Temperature Processing (Anorganic/Sintered)

Processing: Exceeding 300 degrees C, typically 1000 degrees C or higher.

What this does: At these temperatures, everything biological is destroyed. Collagen is incinerated. But more importantly, the hydroxyapatite crystals undergo sintering — they fuse together, dramatically increasing crystallinity and reducing porosity. The native bone architecture is fundamentally altered. What remains is a dense, highly crystalline mineral scaffold.

Why it fails biologically:

RGD sequences destroyed –> no integrin signalling –> M1 macrophage persistence –> osteoclast attachment impaired –> minimal resorption –> permanent particle persistence

The high crystallinity means osteoclasts struggle to dissolve the mineral. The reduced porosity means blood vessels can’t penetrate efficiently. The material persists as particles embedded in fibrous tissue — histology at 11 years shows them “largely unchanged.”

What you get: A scaffold. It holds space. It provides structure. But it does not transform into bone. Volume is maintained through persistence, not through biological turnover.

Examples: Bio-Oss, Cerabone, and other high-temperature sintered bovine bone minerals (DBBM).

Same Endpoint, Two Mechanisms — One Paradigm

Here’s the insight that changes material selection: the Academy doesn’t prefer collagenated materials because of collagen per se. We prefer materials that undergo biological turnover — that get replaced by living, vital bone.

Collagen is one mechanism to achieve that. Preserved native porosity is another.

The discriminator isn’t “does it contain collagen?” It’s “does it get replaced by living bone?”

Both collagen-mediated and porosity-mediated materials achieve this. High-temperature sintered materials do not.

This is why processing matters more than brand name, more than species origin, and more than what your rep told you over lunch. Two materials can both be porcine-derived, both xenogeneic, both “bone graft” — and have completely different biological programmes based on how they were processed.

Histological Timelines: What Actually Happens Over Time

At 6 Months:

Sintered materials (structural persistence): Particles persistent with minimal remodelling. Surrounded by fibrous tissue. Structurally present but biologically inert.

Collagenated and high-porosity materials (biological turnover): Active resorption visible. New bone formation throughout. Dynamic remodelling in progress. In porosity-mediated materials, residual graft already below 12%.

At 12 Months:

Sintered materials: Particles still persistent. Composite tissue — part graft, part fibrous tissue, minimal vital bone. The material is still there.

Collagenated and high-porosity materials: Significant replacement with vital bone. Material being transformed, not just encapsulated. In porosity-mediated materials, residual graft below 6% with new bone exceeding 40%. Trabecular architecture developing.

Long-Term (Years):

Sintered materials: Particles remaining “largely unchanged” even at 11 years. Permanent scaffold embedded in tissue. Volume maintained, but not through bone.

Collagenated and high-porosity materials: Complete turnover potential. Native bone quality. Indistinguishable from natural bone remodelling.

One material maintains volume through persistence. The other maintains volume through transformation.

Which biological programme do you want in your patient’s jaw?

The Regenerative Hierarchy: What to Use When

Understanding the processing-behaviour paradigm gives you a framework for material selection based on biology, not marketing.

Priority 1: Autogenous Bone (Gold Standard)

When to use: Complex defects. Compromised healing (diabetic, smoker, radiation). Maximum biological requirement.

Why it works: Living cells, intact growth factors, complete biological signalling. Nothing beats it for regenerative potential.

Priority 2: Autogenous Plus Biological Turnover Xenograft

When to use: Volume extension beyond what you can harvest. Standard augmentation where you need both biology and volume.

Why it works: Autogenous provides the cellular biology. Collagenated or high-porosity xenograft extends the volume while maintaining the regenerative programme. Both pathways support this combination.

Priority 3: Biological Turnover Xenograft Alone

When to use: Socket preservation. Small to moderate defects. Good host biology.

Why it works: Whether collagen-mediated (preserved RGD sequences supporting M2 polarisation and osteoclast attachment) or porosity-mediated (native architecture enabling osteoclastic resorption through interconnected pore networks), these materials achieve active biological turnover. The graft becomes native bone.

Priority 4: Sintered Xenograft (Not Recommended)

When it’s used: When clinicians don’t understand the processing-behaviour paradigm.

What it achieves: Structural success without biological success. Volume maintained through particle persistence, not bone formation.

The problem: You’re choosing a permanent scaffold when you could choose a transformative material.

The Two Questions You Need to Ask

Material selection is not about brand names. It’s about understanding the biological programme your material delivers.

So here are the two questions:

Question 1: What is the processing temperature?

Below 130 degrees C preserves the conditions for biological turnover — either through collagen retention or through architectural preservation. Above 300 degrees C destroys both pathways and commits you to structural persistence.

Question 2: What is the total porosity?

Above 75% with interconnected macro-, micro-, and nanopores enables rapid vascularisation, cell migration, and osteoclastic engagement — even without collagen. Below 65% (typical of sintered materials) limits biological access and favours persistence.

Those two numbers — temperature and porosity — tell you more about biological behaviour than any brochure, any brand name, or any sales presentation.

At the Academy of Implant Excellence, we teach the biology behind the protocols. Understanding why processing determines graft fate — and that there are two distinct biological pathways to living bone — is one example of the depth that changes material selection. Not because it’s complicated, but because most courses teach “use this brand for sinus lifts” without explaining the biology that determines whether your graft persists or transforms.

And once you understand that biological turnover is the goal, and that both collagen and porosity can get you there, you can’t go back to choosing materials based on which rep bought you lunch.

Ready to Understand the Biology Behind the Protocols?

The Academy of Implant Excellence teaches system-agnostic, biology-first implant training. From single implants to full-arch mastery. 80+ hours of depth that covers the invisible 10% where complications happen.

Because protocols work until they don’t.

Explore Academy Training →

References

Khaira P. Dual-Phase Xenograft Processing Review. Academy of Implant Excellence, 2025.

Lee JH, Yi GS, Lee JW and Kim DJ. Physicochemical characterization of porcine bone-derived grafting material and comparison with bovine xenografts for dental applications. Journal of Periodontal and Implant Science, 2017; 47(6): 388-401.

Soardi CM, Cavani F, Soardi B, Zaffe D and Wang HL. Maxillary sinus floor augmentation with porcine-apatite xenograft: a prospective case series study. International Journal of Periodontics and Restorative Dentistry, 2023; 43(6): 687-697.

Lee JS, Shin HK, Yun JH and Cho KS. Randomized clinical trial of maxillary sinus grafting using deproteinized porcine and bovine bone mineral. Clinical Implant Dentistry and Related Research, 2016; 19(1): 140-150.

Wang X, Cui F et al. Mineralized Collagen Bone Graft Substitutes. Beijing Allgens Medical, 2019.

Khoury F et al. Autogenous Bone Harvesting and Grafting. Quintessence, 2022.

 

Your screening form could be missing five drug classes that can destroy the jawbone. Here’s how you can ensure you don’t miss them. 

The Bisphosphonate Blind Spot

Most implant clinicians have a bisphosphonate protocol down pat: 

Ask about alendronate. Check the duration of therapy. Consider CTX testing. Perhaps request a drug holiday.

You’re doing everything right. Except you’re screening for one pathway to osteonecrosis while missing five others.

Here’s what nobody tells you: bisphosphonates represent just one mechanism of drug-induced osteonecrosis of the jaw. The condition we should actually be calling DIONJ—Drug-Induced Osteonecrosis of the Jaw—has expanded well beyond its original medication associations.

And if your screening form only asks about bisphosphonates, you’re missing patients at significant risk.

Let me show you what’s changed and what you need to be screening for.

Why DIONJ Rather Than MRONJ?

The terminology evolution tells you everything about how our understanding has expanded.

BRONJ (Bisphosphonate-Related ONJ) was the original term, reflecting early identification with bisphosphonate use. Made sense at the time—that’s what we knew.

MRONJ (Medication-Related ONJ) expanded recognition to include denosumab and other antiresorptives. (Getting warmer.)

DIONJ (Drug-Induced ONJ) encompasses all pharmacological agents affecting jaw bone biology. This is the accurate term for current understanding.

The shift from BRONJ to MRONJ to DIONJ isn’t just semantic pedantry—it reflects a fundamental expansion of risk factors that changes how we should screen every implant patient.

The Five Additional Drug Classes (That Aren’t on Your Form)

Right. Let’s get into what you’re actually screening for.

Class 1: Antiangiogenic Agents

These are typically prescribed for metastatic cancer, particularly colorectal, lung, and renal cell carcinoma. Your patient might not volunteer this information unless you ask the right questions.

Examples:
Bevacizumab (Avastin), sunitinib, sorafenib

Mechanism:
VEGF inhibition—blocking vascular endothelial growth factor signalling. Here’s why that matters: VEGF is essential for angiogenesis during wound healing. Block the signalling, compromise the healing.

Jaw impact:
Without adequate angiogenesis, post-surgical bone healing is severely compromised. The tissue can’t rebuild the vascular network it needs.

Risk level: 

High when actively on therapy

Class 2: Tyrosine Kinase Inhibitors (TKIs)

These are commonly prescribed for chronic myeloid leukaemia and gastrointestinal stromal tumours. Again, not information that typically comes up when you ask “Are you on bisphosphonates?”

Examples:
Imatinib (Gleevec), dasatinib, nilotinib

Mechanism:
Targeted inhibition of specific cellular pathways, including those affecting bone metabolism. TKIs don’t just affect cancer cells—they affect normal cellular signalling, including in bone.

Jaw impact:
Multiple pathways of bone metabolism get disrupted. The specifics vary by agent, but the outcome is compromised bone healing and remodelling.

Risk level:
Moderate to high, depending on specific agent and duration

Class 3: Corticosteroids

Long-term steroid use is incredibly common—asthma, COPD, inflammatory bowel disease, rheumatoid arthritis, organ transplant patients. These patients are everywhere in general practice.

Examples:
Prednisone, prednisolone, dexamethasone

Mechanism:
Broad immunosuppression and effects on bone metabolism. Steroids affect virtually every aspect of bone biology—cell proliferation, differentiation, and mineralisation.

Jaw impact:
Suppressed bone formation, impaired healing, increased infection risk.

Critical note:
Corticosteroids invalidate CTX bone turnover testing. This is crucial. A patient on long-term steroids can have a “normal” CTX reading that provides completely false reassurance. The test is meaningless in this population.

Risk level:
Dose and duration dependent, but significant with long-term use

Class 4: mTOR Inhibitors

Typically prescribed for renal cell carcinoma and as immunosuppression in transplant patients. Often used in combination with other agents, which compounds risk.

Examples:
Everolimus (Afinitor), temsirolimus

Mechanism:
Inhibition of the mechanistic target of rapamycin, affecting cell proliferation and survival. mTOR is a critical regulator of cell growth and metabolism.

Jaw impact:
Impaired cellular response to surgical trauma, compromised healing cascade.

Risk level:
Moderate, but additive with other immunosuppressive agents

Class 5: Radiopharmaceuticals

Used specifically for bone metastases from prostate cancer. If your patient has been treated for metastatic prostate cancer, this should trigger immediate inquiry.

Examples:
Radium-223 (Xofigo)

Mechanism:
Delivering targeted radiation to bone tissue. The drug mimics calcium and deposits in areas of high bone turnover—which is exactly where metastases tend to form.

Jaw impact:
Similar considerations to head and neck radiation therapy. The jawbone receives ongoing radiation exposure that compromises its healing capacity and infection resistance.

Risk level:
High

CTX Testing: What It Can and Can’t Tell You

CTX (C-terminal telopeptide) testing measures bone turnover markers. It’s a useful tool when used correctly. But it has significant limitations that can provide false reassurance if you’re not aware of them.

Validity Conditions (When CTX Actually Works)

CTX is only valid when all of these conditions are met:

Miss any of these, and the result is unreliable.

Interpreting Results

CTX below 100 pg/mL indicates severely suppressed bone turnover with high DIONJ risk. This is your red flag.

Critical limitation: CTX is invalid in patients on steroids, methotrexate, or with active cancer. A “normal” result in these populations provides false reassurance. You’re getting a number, but the number doesn’t mean what you think it means.

This matters because many of the patients on the five drug classes above will also be on steroids or have active cancer—exactly the populations where CTX is unreliable.

So what do you do? You rely on the drug history itself, not the biochemical marker. If the patient is on high-risk medications, treat them as high-risk regardless of CTX.

The Screening Form Revolution

Here’s the practical implementation that changes everything.

Current Approach (Inadequate)

“Are you on bisphosphonates?”

This question captures one drug class out of six. You’re screening for 17% of the risk.

Better Approach (Comprehensive)

“Are you taking any medications that affect your bones, blood vessels, or immune system?”

This opens the conversation to the full spectrum of relevant medications.

Specific Probes

Follow up with targeted questions:

These questions capture the clinical scenarios where high-risk medications are prescribed.

Implementation in Practice

Update your medical history form. Train your reception staff on which responses trigger clinical review. Create a protocol for patients who screen positive.

This isn’t complicated. It’s just comprehensive.

The Question You Need to Answer

DIONJ risk assessment must extend beyond bisphosphonates.

Five additional drug classes affect jaw bone biology in ways that compromise surgical outcomes: antiangiogenics, tyrosine kinase inhibitors, corticosteroids, mTOR inhibitors, and radiopharmaceuticals.

Each class has distinct mechanisms, but all share the capacity to impair bone healing and increase osteonecrosis risk.

So here’s the question: How many of these drug classes appear on your current screening form?

If the answer is “none” or “just bisphosphonates,” you’re screening for historical understanding, not current evidence.

At the Academy iof Implant Excellence, we teach the biology behind the protocols. Understanding DIONJ pathophysiology across all relevant drug classes is one example of the depth that changes practice. Not because it’s complicated, but because most training providers are still teaching BRONJ protocols from 2010.

And once you understand the full scope of drug-induced osteonecrosis risk, you can’t go back to asking only about alendronate.

Ready to Understand the Biology Behind the Protocols?

The Academy of Implant Excellence teaches system-agnostic, biology-first implant training. From single implants to full-arch mastery. 80+ hours of depth that covers the invisible 10% where complications happen.

Because protocols work until they don’t.

Explore Academy Training →

References

  1. Marx RE. Oral and Maxillofacial Pathology. In: Hupp JR et al. Contemporary Oral and Maxillofacial Surgery. 7th ed. Elsevier, 2024.

  2. Ruggiero SL et al. AAOMS Position Paper on MRONJ—2022 Update. J Oral Maxillofac Surg. 2022.

  3. Resnik RR, Misch CE. Misch’s Avoiding Complications in Oral Implantology. Elsevier, 2018.

Your implants are ageing. Right now. In the drawer.

Every Implant Has a Birthday

The day it was manufactured, sterilised, and sealed in packaging. From that moment, a biological clock starts ticking.

And here’s what nobody tells you: this clock measures the progressive degradation of surface bioactivity—hydrocarbon contamination from just sitting in the atmosphere. So, by the time an implant reaches your surgical tray, weeks or months after manufacture, it’s no longer biologically fresh.

The phenomenon is called biological ageing, and understanding it fundamentally changes how you think about implant success and failure.

More importantly, there’s a protocol that reverses it: photofunctionalisation.

Let me show you the mechanism, the evidence, and the clinical protocol that can transform outcomes in your practice.

What They Don’t Teach You

Traditional implant education focuses on what you control: surgical technique, bone quality assessment, primary stability, loading protocols, and prosthetic design.

These matter. (Obviously.) But they don’t tell the whole story.

What conventional training overlooks—and I mean completely overlooks—is that the implant itself is a biological variable. The surface that contacts bone isn’t static. It changes over time, and not for the better.

Most courses teach surface roughness as if it’s the only thing that matters. You learn about SLA, anodisation, and micro-topography for osteoblast attachment—all important stuff.

What you don’t learn is that these carefully engineered surfaces start degrading the moment they’re exposed to air.

I spent years placing implants before I understood this, genuinely wondering why some cases in “good bone” struggled, why identical techniques produced different outcomes.

I’d review everything: Did we achieve adequate primary stability? Was healing sufficient? Could there have been contamination?

All reasonable questions. All missing the point.

Because the root cause predated the surgery entirely: The implant was already compromised before I opened the package.

The Biology They Should Have Taught You

Titanium isn’t biologically inert. The oxide layer that forms on titanium surfaces, the layer responsible for biocompatibility, actively interacts with its environment.

In sterile manufacturing conditions, this surface has high surface energy and excellent hydrophilicity, perfect for blood contact, protein adsorption, and cell attachment.

Once it’s exposed to air, hydrocarbons start depositing on the surface. You can’t see it, can’t smell it, but it’s happening.

Within four weeks of manufacture, the surface properties have measurably degraded. Four weeks. That’s it.

The Ogawa Research (Or: The Data That Should Change Everything)

The research quantifying this comes primarily from Takahiro Ogawa and colleagues at UCLA. Their work demonstrated that aged titanium surfaces show:

Reduced surface energy

Increased water contact angle (loss of hydrophilicity)

Reduced osteoblast attachment by approximately 50%

Compromised bone-to-implant contact potential

The biological consequence? Significant doesn’t even cover it.

Fresh surfaces achieve BIC values that aged surfaces simply cannot match. In controlled studies, aged surfaces achieved approximately 55% BIC while photofunctionalised surfaces achieved 98.2% BIC.

Read that again. 55% versus 98.2%.

This isn’t a marginal difference—this is a fundamentally different biological response. Same implant design, same surgical technique, completely different biology.

Why This Happens

The mechanism is straightforward once you understand it. Hydrocarbons on the surface interfere with the initial protein adsorption cascade that precedes cell attachment. When blood contacts a contaminated surface, the biological signalling that recruits osteoblasts gets compromised.

The implant still integrates. Sure. But not optimally.

The surface that could have achieved near-complete bone contact settles for partial integration, and you never know what you’ve left on the table.

This explains those clinical observations that used to drive me mad: Why do some implants perform better than others in identical conditions? Why does the same surgeon see different healing patterns with the same implant system? Why do some cases in “favourable” conditions still struggle?

Surface age is one variable among many, but it’s been systematically overlooked. And that needs to change.

Clinical Implications: When Surface Conditioning Actually Matters

Understanding biological ageing reframes how you make clinical decisions. Instead of treating all implants as equivalent (which they’re not), you can stratify risk based on what you actually know.

Strong Indications for Photofunctionalisation

Compromised host situations where optimal integration is critical:

You know the patients I’m talking about: diabetic patients with HbA1c at the upper acceptable limit, history of smoking (recently quit), older patients with reduced bone density.

Any systemic factor that narrows the margin between success and failure. In these cases, every biological advantage matters.

Immediate loading protocols where rapid stability is required:

Here’s what the research shows: the characteristic ISQ dip at three weeks—that period when primary mechanical stability transitions to secondary biological stability—gets eliminated with photofunctionalised surfaces.

This means loading timelines can potentially be compressed in appropriate cases.

Immediate loading criteria expand, and the margin of safety in challenging cases increases.

Cases with marginal primary stability where you need every advantage:

Type IV bone, compromised extraction sockets, and situations where the mechanical foundation is less than ideal. You’re already on the edge—why wouldn’t you optimise the biology?

Moderate Indications

Implants stored longer than four weeks:

If you’re unsure how long an implant has been sitting in your inventory (and let’s be honest, who actually tracks this?), surface conditioning provides insurance.

Final abutment placement:

Soft tissue integration benefits from surface conditioning with argon plasma. Research from Canullo and colleagues has demonstrated benefits particularly for abutment surfaces.

The Evidence on Outcomes

Funato and colleagues demonstrated that photofunctionalised implants reach a stability plateau in 2 months compared to 4 months for untreated surfaces. The characteristic stability dip at three weeks? Gone.

So, immediate loading criteria expand, the margin of safety in challenging cases increases, and loading timelines compress in appropriate cases. All from treating the surface properly.

Important caveat—and I mean this:

Photofunctionalisation does not replace sound surgical principles. It enhances the biological response to surgery that’s already performed correctly. You can’t rescue poor surgical technique with surface treatment. Don’t even try.

The Protocol Framework

How Photofunctionalisation Works

You expose the implant surface to UV-C light at 254nm wavelength. This specific wavelength has sufficient energy to break the carbon-carbon and carbon-hydrogen bonds in hydrocarbon contaminants. The treatment removes the contamination layer and restores superhydrophilicity.

Treatment duration: Varies by device. 12–48 minutes for old school devices. Modern devices take just 60 secs. (Yes, that quick!)

Critical timing: Treatment must be performed immediately before placement. The refreshed surface will begin accumulating contaminants upon atmospheric exposure.

Clinical Decision Gates

Here’s where most courses hedge: “It depends.” Yeah. I’m not doing that.

STRONG RECOMMENDATION:

Compromised host situations

Immediate loading protocols

MODERATE RECOMMENDATION:

Implants stored > 4 weeks

Cases with low primary stability

Final abutment placement (consider argon plasma or UV-C)

Clear enough?

Practical Implementation

The workflow integration is about as straightforward as it gets.

Place the UV-C device in your surgical suite. While you’re preparing the surgical site, the implant is being treated. By the time your osteotomy is complete, the implant is ready with a freshly activated surface.

The workflow adds minimal time. The biological advantage is potentially significant. Worth it? Absolutely.

Alternative: Argon Plasma Treatment

Similar mechanism—removing organic contamination. Research from Canullo and colleagues has demonstrated benefits particularly for abutment surfaces where soft tissue integration is the priority. Another tool in the arsenal.

The Question You Need to Answer

Biological ageing is not theoretical. It’s documented, measurable, clinical, and real.

The evidence base supports surface conditioning as a method to optimise outcomes, particularly in cases where the margin for error is narrow.

The question isn’t whether your implants age. They do. Right now. In your drawer.

The question is whether you’ll continue treating all surfaces as equivalent, or whether you’ll integrate this knowledge into your clinical decision-making.

Can you skip photofunctionalisation? Sure. The 90% of straightforward cases will probably be fine.

But here’s the thing:

If you’re reading this, you’re not interested in “probably fine.” You’re interested in understanding the invisible 10%—the biological variables that separate predictable integration from cases that struggle. You want to stack every biological advantage in your patient’s favour when the margin between success and failure narrows.

That’s the difference between competence and mastery.

At the Academy, we teach the biology behind the protocols. Understanding biological ageing is one example of the depth that changes practice. Not because it’s complicated, but because most clinicians never learned it.

And once you understand it, you can’t unknow it. Excellence stops being optional.

Ready to Understand the Biology Behind the Protocols?

The Academy of Implant Excellence teaches system-agnostic, biology-first implant training. From single implants to full-arch mastery. 80+ hours of depth that covers the invisible 10% where complications happen.

Because protocols work until they don’t.

Explore Academy Training →

References

  1. Att W, Ogawa T. Biological aging of implant surfaces and their restoration with ultraviolet light treatment: a novel understanding of osseointegration. Int J Oral Maxillofac Implants. 2012;27(4):753-761.
  2. Aita H, Hori N, Takeuchi M, et al. The effect of ultraviolet functionalization of titanium on integration with bone. Biomaterials. 2009;30(6):1015-1025.
  3. Funato A, Yamada M, Ogawa T. Success rate, healing time, and implant stability of photofunctionalized dental implants. Int J Oral Maxillofac Implants. 2013;28(5):1261-1271.
  4. Ogawa T. Ultraviolet photofunctionalization of titanium implants. Int J Oral Maxillofac Implants. 2014;29(1):e95-e102.
  5. Canullo L, Tallarico M, Unique A, et al. Plasma of argon treatment of the implant surface for soft tissue integration: a pilot study. Clin Implant Dent Relat Res. 2023;25(1):117-125.
  6. Elkhidir Y, Cheng Y. Photofunctionalization of titanium implants: an alternative approach. J Dent. 2017;61:54-59.
  7. Suzuki T, Hori N, Oharai Y, et al. Ultraviolet treatment overcomes time-related degrading bioactivity of titanium. Tissue Eng Part A. 2009;15(12):3679-3688.